Evaluation of Antiplatelet Therapy Related to Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) Values in Relation to the Risk of Recurrent Stroke
Main Article Content
Stroke is a medical emergency with significant mortality and morbidity, often influenced by platelet aggregation. Antiplatelet agents are crucial in stroke prevention, as they inhibit platelet function and reduce thrombus formation. Despite antiplatelet therapy, some patients experience recurrent strokes, necessitating further investigation into coagulation parameters like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT). This study aims to explore the relationship between antiplatelet therapy and PT/APTT values in stroke patients to assess the risk of recurrent strokes. A comparative study was conducted on two groups of stroke patients: those using aspirin therapy and those not using it. PT and APTT measurements were taken at the start and end of a three-month observation period. Data were analyzed quantitatively, focusing on PT and APTT changes in each group. Results: PT values increased more significantly in the Non-Aspirin group (16.32%) compared to the Aspirin group (11.98%). APTT values also increased more in the Non-Aspirin group (4.97%) compared to the Aspirin group (4.73%). However, the statistical significance of the differences in PT and APTT between the groups was not observed (p > 0.05). The study concludes that there is no significant difference in PT and APTT values between patients using clopidogrel alone or in combination with aspirin, indicating no enhanced risk of recurrent strokes based on these parameters.
Brown, D. L., Levine, D. A., Albright, K., Kapral, M. K., Leung, L. Y., Reeves, M. J., Sico, J., Strong, B., Whiteley, W. N., & Council, A. H. A. S. (2021). Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke, 52(7), e468–e479.
Chen, Z., Mo, J., Xu, J., Dai, L., Cheng, A., Yalkun, G., Wang, A., Meng, X., Li, H., & Wang, Y. (2020). Effect of low diastolic blood pressure to cardiovascular risk in patients with ischemic stroke or transient ischemic attacks under different systolic blood pressure levels. Frontiers in Neurology, 11, 356.
Geng, L., Pan, K., Xu, Y., Zhang, B., Wang, J., Xue, Q., Zhang, S., Su, H., & Zhang, B. (2024). Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 33(9), 107885. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107885
Glans, I., Nägga, K., Gustavsson, A.-M., Stomrud, E., Nilsson, P. M., Melander, O., Hansson, O., & Palmqvist, S. (2024). Associations of modifiable and non-modifiable risk factors with cognitive functions–a prospective, population-based, 17 years follow-up study of 3,229 individuals. Alzheimer’s Research & Therapy, 16(1), 135.
Hyatt, C. E., & Brainard, B. M. (2016). Point of Care Assessment of Coagulation. Topics in Companion Animal Medicine, 31(1), 11–17. https://doi.org/10.1053/j.tcam.2016.05.002
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., Stevens, S. M., Vintch, J. R. E., Wells, P., Woller, S. C., & Moores, L. (2016). Antithrombotic Therapy for VTE Disease. Chest, 149(2), 315–352. https://doi.org/10.1016/j.chest.2015.11.026
Li, X., Guo, T., Feng, Q., Bai, T., Wu, L., Liu, Y., Zheng, X., Jia, J., Pei, J., Wu, S., Song, Y., & Zhang, Y. (2022). Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs. European Journal of Medicinal Chemistry, 228, 114035. https://doi.org/10.1016/j.ejmech.2021.114035
McFadyen, J. D., Schaff, M., & Peter, K. (2018). Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nature Reviews Cardiology, 15(3), 181–191.
McKenna, C., Chen, P., & Barrett, A. M. (2017). Stroke: Impact on life and daily function. Changes in the Brain: Impact on Daily Life, 87–115.
Mehari, E. A., Mekuria, A. B., Geta, M., & Birru, E. M. (2023). Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia. Thrombosis Update, 10, 100130. https://doi.org/10.1016/j.tru.2023.100130
Menegatti, M., & Palla, R. (2020). Clinical and laboratory diagnosis of rare coagulation disorders (RCDs). Thrombosis Research, 196, 603–608. https://doi.org/10.1016/j.thromres.2019.09.006
Murphy, S. JX., & Werring, D. J. (2020). Stroke: causes and clinical features. Medicine, 48(9), 561–566. https://doi.org/10.1016/j.mpmed.2020.06.002
Pan, Y., Elm, J. J., Li, H., Easton, J. D., Wang, Y., Farrant, M., Meng, X., Kim, A. S., Zhao, X., & Meurer, W. J. (2019). Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurology, 76(12), 1466–1473.
Price, J. E. (2015). Stroke: What preventative education occurs in primary care? A retrospective review of primary care prevention, post stroke. State University of New York at Binghamton.
Proietti, M., Lane, D. A., Boriani, G., & Lip, G. Y. H. (2019). Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. Canadian Journal of Cardiology, 35(5), 619–633. https://doi.org/10.1016/j.cjca.2019.02.009
Ryczkowska, K., Adach, W., Janikowski, K., Banach, M., & Bielecka-Dabrowa, A. (2023). Menopause and women’s cardiovascular health: is it really an obvious relationship? Archives of Medical Science: AMS, 19(2), 458.
Sandercock, P. A. G., Counsell, C., Tseng, M., & Cecconi, E. (2014). Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews, 3.
Tekle, E., Gelaw, Y., Dagnew, M., Gelaw, A., Negash, M., Kassa, E., Bizuneh, S., Wudineh, D., & Asrie, F. (2022). Risk stratification and prognostic value of prothrombin time and activated partial thromboplastin time among COVID-19 patients. PLoS One, 17(8), e0272216.
Xian, Y., Hernandez, A. F., Harding, T., Fonarow, G. C., Bhatt, D. L., Suter, R. E., Khan, Y., Schwamm, L. H., & Peterson, E. D. (2016a). Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal, 182, 28–35. https://doi.org/10.1016/j.ahj.2016.07.023
Xian, Y., Hernandez, A. F., Harding, T., Fonarow, G. C., Bhatt, D. L., Suter, R. E., Khan, Y., Schwamm, L. H., & Peterson, E. D. (2016b). Acute management of stroke patients taking non–vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American Heart Journal, 182, 28–35. https://doi.org/10.1016/j.ahj.2016.07.023